A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Condition(s) studied
Investigational drug(s) / intervention(s)
SSGJ-716: Single and multiple subcutaneous injection
Placebo: Single and multiple subcutaneous injection
Study summary
The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD).
The study has two parts. The first part (Single Ascending Dose, SAD) will enroll healthy adults.The second part (Multiple Ascending Dose, MAD) will enroll participants with moderate-to-severe AD.
Eligibility
Primary outcome measure(s)
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) — 85 days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Huashan Hospital, Fudan University | Shanghai | China | Recruiting |
More Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07693738 on ClinicalTrials.gov ↗ ← All trials in China